Activation of PDGFr-β Signaling Pathway after Imatinib and Radioimmunotherapy Treatment in Experimental Pancreatic Cancer

Activation of PDGFr-β Signaling Pathway after Imatinib and Radioimmunotherapy Treatment in Experimental Pancreatic Cancer

Pancreatic cancer does not respond to a single-agent imatinib therapy. Consequently, multimodality treatments are contemplated. Published data indicate that in colorectal cancer, imatinib and radioimmunotherapy synergize to delay tumor growth. In pancreatic cancer, the tumor response is additive. Th...

Full description

Bibliographic Details
Main Authors: Elizabeth Mack, Michio Abe, Zbigniew P. Kortylewicz, Charles A. Enke, Janina Baranowska-Kortylewicz
Format: Article
Language:English
Published: MDPI AG 2011-05-01
Series:Cancers
Subjects:
pancreatic cancer
PDGFr-β
PDGF-B
imatinib
radioimmunotherapy
radiation
Online Access:http://www.mdpi.com/2072-6694/3/2/2501/

Internet

http://www.mdpi.com/2072-6694/3/2/2501/

Similar Items